These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 30667343)

  • 1. A SMN2 Splicing Modifier Rescues the Disease Phenotypes in an In Vitro Human Spinal Muscular Atrophy Model.
    Son YS; Choi K; Lee H; Kwon O; Jung KB; Cho S; Baek J; Son B; Kang SM; Kang M; Yoon J; Shen H; Lee S; Oh JH; Lee HA; Lee MO; Cho HS; Jung CR; Kim J; Cho S; Son MY
    Stem Cells Dev; 2019 Apr; 28(7):438-453. PubMed ID: 30667343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of spinal muscular atrophy via correction of the SMN2 splicing defect by Brucea javanica (L.) Merr. extract and Bruceine D.
    Baek J; Jeong H; Ham Y; Jo YH; Choi M; Kang M; Son B; Choi S; Ryu HW; Kim J; Shen H; Sydara K; Lee SW; Kim SY; Han SB; Oh SR; Cho S
    Phytomedicine; 2019 Dec; 65():153089. PubMed ID: 31563042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophy.
    Kletzl H; Marquet A; Günther A; Tang W; Heuberger J; Groeneveld GJ; Birkhoff W; Mercuri E; Lochmüller H; Wood C; Fischer D; Gerlach I; Heinig K; Bugawan T; Dziadek S; Kinch R; Czech C; Khwaja O
    Neuromuscul Disord; 2019 Jan; 29(1):21-29. PubMed ID: 30553700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, pharmacodynamics, and efficacy of a small-molecule SMN2 splicing modifier in mouse models of spinal muscular atrophy.
    Zhao X; Feng Z; Ling KK; Mollin A; Sheedy J; Yeh S; Petruska J; Narasimhan J; Dakka A; Welch EM; Karp G; Chen KS; Metzger F; Ratni H; Lotti F; Tisdale S; Naryshkin NA; Pellizzoni L; Paushkin S; Ko CP; Weetall M
    Hum Mol Genet; 2016 May; 25(10):1885-1899. PubMed ID: 26931466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells.
    Pagliarini V; Guerra M; Di Rosa V; Compagnucci C; Sette C
    J Neurochem; 2020 Apr; 153(2):264-275. PubMed ID: 31811660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Securinine enhances SMN2 exon 7 inclusion in spinal muscular atrophy cells.
    Chen YC; Chang JG; Liu TY; Jong YJ; Cheng WL; Yuo CY
    Biomed Pharmacother; 2017 Apr; 88():708-714. PubMed ID: 28152480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling the differential phenotypes of spinal muscular atrophy with high-yield generation of motor neurons from human induced pluripotent stem cells.
    Lin X; Li JJ; Qian WJ; Zhang QJ; Wang ZF; Lu YQ; Dong EL; He J; Wang N; Ma LX; Chen WJ
    Oncotarget; 2017 Jun; 8(26):42030-42042. PubMed ID: 28159932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Established Stem Cell Model of Spinal Muscular Atrophy Is Applicable in the Evaluation of the Efficacy of Thyrotropin-Releasing Hormone Analog.
    Ohuchi K; Funato M; Kato Z; Seki J; Kawase C; Tamai Y; Ono Y; Nagahara Y; Noda Y; Kameyama T; Ando S; Tsuruma K; Shimazawa M; Hara H; Kaneko H
    Stem Cells Transl Med; 2016 Feb; 5(2):152-63. PubMed ID: 26683872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy.
    Naryshkin NA; Weetall M; Dakka A; Narasimhan J; Zhao X; Feng Z; Ling KK; Karp GM; Qi H; Woll MG; Chen G; Zhang N; Gabbeta V; Vazirani P; Bhattacharyya A; Furia B; Risher N; Sheedy J; Kong R; Ma J; Turpoff A; Lee CS; Zhang X; Moon YC; Trifillis P; Welch EM; Colacino JM; Babiak J; Almstead NG; Peltz SW; Eng LA; Chen KS; Mull JL; Lynes MS; Rubin LL; Fontoura P; Santarelli L; Haehnke D; McCarthy KD; Schmucki R; Ebeling M; Sivaramakrishnan M; Ko CP; Paushkin SV; Ratni H; Gerlach I; Ghosh A; Metzger F
    Science; 2014 Aug; 345(6197):688-93. PubMed ID: 25104390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and characterization of an SMN2-based intermediate mouse model of Spinal Muscular Atrophy.
    Cobb MS; Rose FF; Rindt H; Glascock JJ; Shababi M; Miller MR; Osman EY; Yen PF; Garcia ML; Martin BR; Wetz MJ; Mazzasette C; Feng Z; Ko CP; Lorson CL
    Hum Mol Genet; 2013 May; 22(9):1843-55. PubMed ID: 23390132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-(N-ethyl-N-isopropyl)-amiloride enhances SMN2 exon 7 inclusion and protein expression in spinal muscular atrophy cells.
    Yuo CY; Lin HH; Chang YS; Yang WK; Chang JG
    Ann Neurol; 2008 Jan; 63(1):26-34. PubMed ID: 17924536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia is a modifier of SMN2 splicing and disease severity in a severe SMA mouse model.
    Bebee TW; Dominguez CE; Samadzadeh-Tarighat S; Akehurst KL; Chandler DS
    Hum Mol Genet; 2012 Oct; 21(19):4301-13. PubMed ID: 22763238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ZPR1 prevents R-loop accumulation, upregulates SMN2 expression and rescues spinal muscular atrophy.
    Kannan A; Jiang X; He L; Ahmad S; Gangwani L
    Brain; 2020 Jan; 143(1):69-93. PubMed ID: 31828288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triptolide increases transcript and protein levels of survival motor neurons in human SMA fibroblasts and improves survival in SMA-like mice.
    Hsu YY; Jong YJ; Tsai HH; Tseng YT; An LM; Lo YC
    Br J Pharmacol; 2012 Jun; 166(3):1114-26. PubMed ID: 22220673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model.
    Hua Y; Sahashi K; Rigo F; Hung G; Horev G; Bennett CF; Krainer AR
    Nature; 2011 Oct; 478(7367):123-6. PubMed ID: 21979052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of human survival motor neuron (SMN) protein in mice containing the SMN2 transgene: applicability to preclinical therapy development for spinal muscular atrophy.
    Mattis VB; Butchbach ME; Lorson CL
    J Neurosci Methods; 2008 Oct; 175(1):36-43. PubMed ID: 18771690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific Correction of Alternative Survival Motor Neuron 2 Splicing by Small Molecules: Discovery of a Potential Novel Medicine To Treat Spinal Muscular Atrophy.
    Ratni H; Karp GM; Weetall M; Naryshkin NA; Paushkin SV; Chen KS; McCarthy KD; Qi H; Turpoff A; Woll MG; Zhang X; Zhang N; Yang T; Dakka A; Vazirani P; Zhao X; Pinard E; Green L; David-Pierson P; Tuerck D; Poirier A; Muster W; Kirchner S; Mueller L; Gerlach I; Metzger F
    J Med Chem; 2016 Jul; 59(13):6086-100. PubMed ID: 27299419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells.
    Riessland M; Brichta L; Hahnen E; Wirth B
    Hum Genet; 2006 Aug; 120(1):101-10. PubMed ID: 16724231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy.
    Thurmond J; Butchbach ME; Palomo M; Pease B; Rao M; Bedell L; Keyvan M; Pai G; Mishra R; Haraldsson M; Andresson T; Bragason G; Thosteinsdottir M; Bjornsson JM; Coovert DD; Burghes AH; Gurney ME; Singh J
    J Med Chem; 2008 Feb; 51(3):449-69. PubMed ID: 18205293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate.
    Garbes L; Riessland M; Hölker I; Heller R; Hauke J; Tränkle C; Coras R; Blümcke I; Hahnen E; Wirth B
    Hum Mol Genet; 2009 Oct; 18(19):3645-58. PubMed ID: 19584083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.